<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MSJ</journal-id>
<journal-id journal-id-type="hwp">spmsj</journal-id>
<journal-id journal-id-type="nlm-ta">Mult Scler</journal-id>
<journal-title>Multiple Sclerosis Journal</journal-title>
<issn pub-type="ppub">1352-4585</issn>
<issn pub-type="epub">1477-0970</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1352458512451659</article-id>
<article-id pub-id-type="publisher-id">10.1177_1352458512451659</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Distinct features between longitudinally extensive transverse myelitis presenting with and without anti-Aquaporin 4 antibodies</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Chang</surname><given-names>K-H</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Lyu</surname><given-names>R-K</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>C-M</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Wu</surname><given-names>Y-R</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chang</surname><given-names>H-S</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>C-C</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Kuo</surname><given-names>H-C</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chu</surname><given-names>C-C</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Hsu</surname><given-names>W-C</given-names></name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ro</surname><given-names>L-S</given-names></name>
</contrib>
<aff id="aff1-1352458512451659">Section of Neuromuscular Diseases, Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center and University College of Medicine, Taiwan</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-1352458512451659">Long-Sun Ro, Section of Neuromuscular Diseases, Department of Neurology, Chang Gung Memorial Hospital, 199 Tung Hwa North Road, Taipei, 10591, Taiwan. Email: <email>cgrols@adm.cgmh.org.tw</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>19</volume>
<issue>3</issue>
<fpage>299</fpage>
<lpage>307</lpage>
<history>
<date date-type="received">
<day>1</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>25</day>
<month>3</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>14</day>
<month>5</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1352458512451659">
<title>Objectives:</title>
<p>Longitudinally extensive transverse myelitis (LETM) with spinal cord lesions spanning three or more vertebral segments is a key feature of neuromyelitis optica (NMO). However, the role of anti-aquaporin 4 (anti-AQP4) antibody, a sensitive biomarker of NMO, in the conversion of LETM to NMO remains uncertain.</p>
</sec>
<sec id="section2-1352458512451659">
<title>Methods:</title>
<p>Thirty first-ever LETM patients were retrospectively analysed and divided into two groups according to the presence of anti-AQP4 antibodies.</p>
</sec>
<sec id="section3-1352458512451659">
<title>Results:</title>
<p>Eighteen (60%) patients presented with anti-AQP4 antibodies. Fifteen (83.33%) anti-AQP4 (+) LETM patients converted to NMO, while only three of 12 (25%, <italic>p</italic> = 0.002) anti-AQP4 (-) LETM patients progressed to NMO, over a mean follow-up period of 5.63 years. Seven (38.89%) anti-AQP4 (+) and one (8.33%) anti-AQP4 (-) LETM patients received interferon-β1a treatment, respectively. Anti-AQP4 (+) LETM patients demonstrated a higher immunogamma globulin (IgG) index (0.68 ± 0.43 versus 0.47 ± 0.19, <italic>p</italic> = 0.018), annual relapse rate (0.72 ± 0.31 versus 0.42 ± 0.17, <italic>p</italic> = 0.01) and Kurtzke Expanded Disability Status Scale (4.28 ± 2.22 versus 2.67 ± 2.26, <italic>p</italic> = 0.031), than anti-AQP4 (-) LETM patients. In spinal magnetic resonance imaging (MRIs), more than half (58.33%) of the anti-AQP4 (+) LETM patients were observed to have central grey matter-predominant involvement in the axial view, while peripheral white matter-predominant involvement (51.85%) was the most common pattern observed in the anti-AQP4 (-) LETM patients.</p>
</sec>
<sec id="section4-1352458512451659">
<title>Conclusion:</title>
<p>Anti-AQP4 (+) LETM demonstrated a high conversion rate to NMO (83.33%), suggesting that anti-AQP4 (+) LETM may represent an early, isolated syndrome of NMO spectrum disorder. The greater number of patients receiving interferon-β treatment in anti-AQP4 (+) LETM may contribute to its high annual relapse rate.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Neuromyelitis optica</kwd>
<kwd>multiple sclerosis</kwd>
<kwd>anti-Aquaporin 4 antibody</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section5-1352458512451659" sec-type="intro">
<title>Introduction</title>
<p>Neuromyelitis optica (NMO) is an acquired, heterogeneous inflammatory disorder, which is characterised by recurrent optic neuritis and longitudinally extensive spinal cord lesions (LESCLs).<sup><xref ref-type="bibr" rid="bibr1-1352458512451659">1</xref></sup> Although NMO typically has a relapsing–remitting course and is regarded as a variant of multiple sclerosis (MS), it presents clinical features that are different from those of MS.<sup><xref ref-type="bibr" rid="bibr2-1352458512451659">2</xref></sup> Compared with MS, NMO has several distinct characteristics, including higher age at onset, female predominance, greater disability due to severe optic nerve and spinal cord damage, fewer brain magnetic resonance imaging (MRI) lesions, longitudinally extensive spinal cord lesions (LESCLs) extending equal to or greater than three vertebral segments (VBs), marked pleocytosis and neutrophilia in cerebrospinal fluid (CSF) and absence of oligoclonal bands (OCBs) in CSF.<sup><xref ref-type="bibr" rid="bibr2-1352458512451659">2</xref>,<xref ref-type="bibr" rid="bibr3-1352458512451659">3</xref></sup> The discovery of the serum autoantibody marker, anti-aquaporin 4 (anti-AQP4) antibody, further supports the notion that NMO and MS are distinct disease entities.<sup><xref ref-type="bibr" rid="bibr4-1352458512451659">4</xref></sup></p>
<p>Although LESCLs are thought to be the core presentation of NMO, a number of patients with LESCLs do not develop optic neuritis and are subsequently diagnosed with idiopathic longitudinally extensive transverse myelitis (LETM).<sup><xref ref-type="bibr" rid="bibr5-1352458512451659">5</xref></sup> Although it has been shown that LETM patients carrying anti-AQP4 antibody are prone to relapse and proposed to be a part of the NMO spectrum,<sup><xref ref-type="bibr" rid="bibr2-1352458512451659">2</xref>,<xref ref-type="bibr" rid="bibr6-1352458512451659">6</xref></sup> it remains undetermined whether there are any clinical differences between LETM patients with or without anti-AQP4 antibodies. Moreover, there is little information regarding whether the presence of anti-AQP4 antibodies is crucial to the early discrimination of NMO from idiopathic LETM. In this study, we aimed to answer these questions by comparing the clinical features of anti-AQP4 (+) and anti-AQP4 (-) LETM patients. This information is critical to clarify the role of anti-AQP4 antibodies in patients with LETM.</p>
</sec>
<sec id="section6-1352458512451659" sec-type="methods">
<title>Subjects and methods</title>
<sec id="section7-1352458512451659">
<title>Ethics statement</title>
<p>This retrospective analysis was performed under a protocol that was approved by the institutional review boards of the Chang Gung Memorial Hospital (ethical license No: 100-1083B), and all examinations were performed after obtaining written informed consent.</p>
</sec>
<sec id="section8-1352458512451659">
<title>Study population</title>
<p>Thirty-two patients with first-ever LETM with spinal cord lesions continuously extending to or over three VBs were retrospectively recruited from the Linkou Chang Gung Memorial Hospital, a tertiary referral medical centre in Taiwan, from January 1993 to September 2011. Two patients, subsequently diagnosed as having systemic lupus erythematosus and Sjögren syndrome, were excluded. Among the remaining 30 patients, none had Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, vasculitis, malignancies, or human T-cell leukaemia virus type 1 or human immunodeficiency virus infections.</p>
</sec>
<sec id="section9-1352458512451659">
<title>Data collection</title>
<p>A standard case collection form was used to record the age of onset, gender, onset symptoms, nervous systems involved in each episode, temporal course, number of attacks, intervals between episodes, haematological and biochemical profiles, brain and spinal cord MRIs and treatment. All patients underwent collagen vascular disease screenings. Analysis of the CSF, serum anti-AQP4 and other autoantibodies, evoked potentials (EPs) and MRIs were performed within two weeks after attack. The diagnosis of NMO and MS was based on Wingerchuk’s criteria in 2006 and McDonald’s criteria in 2010, respectively.<sup><xref ref-type="bibr" rid="bibr3-1352458512451659">3</xref>,<xref ref-type="bibr" rid="bibr7-1352458512451659">7</xref></sup> A relapse of LETM was defined as the occurrence, recurrence, or worsening of the symptoms of neurological dysfunction that lasted more than 24 hours, and then stabilised or eventually resolved, either partially or completely.<sup><xref ref-type="bibr" rid="bibr8-1352458512451659">8</xref></sup> Symptoms that occurred within one month after the initial symptoms of relapse were considered to be part of the same episode.<sup><xref ref-type="bibr" rid="bibr8-1352458512451659">8</xref></sup> A corticosteroid (1,000 mg methylprednisone, administered intravenously for five consecutive days) was prescribed in the acute stage, and some patients received interferon-β1a or azathioprine in the remission stage. The neurological disability of the patients was assessed using the Kurtzke Expanded Disability Status Scale (EDSS) based on the results of the neurological examination and ambulatory ability assessment.<sup><xref ref-type="bibr" rid="bibr9-1352458512451659">9</xref></sup> All EP studies were performed according to standard procedures. The limits of normal values in different EP modalities (visual evoked potential (VEP), brainstem auditory evoked potential (BAEP), motor evoked potential (MEP) and somatosensory evoked potential (SSEP)) were based on publications from Chang Gung Memorial Hospital.<sup><xref ref-type="bibr" rid="bibr10-1352458512451659">10</xref><xref ref-type="bibr" rid="bibr11-1352458512451659"/>–<xref ref-type="bibr" rid="bibr12-1352458512451659">12</xref></sup></p>
<p>The immunogamma globulin (IgG) index was defined as the quotient between IgG and albumin of the CSF and serum. The standard isoelectric focusing method was used to detect OCBs in the CSF specimens during the study period.<sup><xref ref-type="bibr" rid="bibr13-1352458512451659">13</xref></sup> Serum anti-AQP4 antibodies were tested in all patients according to the methodology described by Matsuoka et al.<sup><xref ref-type="bibr" rid="bibr14-1352458512451659">14</xref></sup> MRI scans were taken at the time of the clinical relapse, with protocols including T1-, T1-enhanced and T2-weighted images. Fluid-attenuated inversion recovery sequencing was also applied to brain MRIs. The length of the spinal cord lesions was expressed in terms of the number of vertebral segments. A cross-sectional evaluation was also performed on all MRI scans of the spinal cord, and lesions were classified as either having a holocord pattern, a central grey matter-predominant pattern, or a peripheral white matter-predominant pattern.<sup><xref ref-type="bibr" rid="bibr15-1352458512451659">15</xref></sup> Brain MRI lesions that fulfilled the Barkhof criteria were classified as the ‘Barkhof brain lesion’ group.<sup><xref ref-type="bibr" rid="bibr16-1352458512451659">16</xref></sup> Brain MRI lesions that did not satisfy Barkhof’s criteria were classified as the ‘lesions not fulfilling Barkhof criteria’ group. Brain MRIs that displayed no structural abnormalities were classified as the ‘Normal’ group. Radiologists who were blinded to the study group designations reported the results of all MRIs.</p>
</sec>
<sec id="section10-1352458512451659">
<title>Statistical analysis</title>
<p>All statistical analyses were performed using Statistical Program for Social Sciences (SPSS) statistical software (version 13.0; Chicago, IL, USA). For each set of values, data were expressed as the means ± standard deviation (SD). Categorical variables were compared using Fisher’s exact test. Non-categorical variables were compared using the Mann-Whitney <italic>U</italic> test. Survival was estimated according to the Kaplan-Meier method. The primary study endpoint was the time to NMO conversion, as indicated by the Winger-chuk’s criteria.<sup><xref ref-type="bibr" rid="bibr3-1352458512451659">3</xref></sup> The log-rank test was used to compare the survival analysis between anti-AQP4 (+) and anti-AQP4 (-) LETM patients. All <italic>p</italic>-values were two-tailed, with values of <italic>p</italic> &lt; 0.05 considered significant.</p>
</sec>
</sec>
<sec id="section11-1352458512451659" sec-type="results">
<title>Results</title>
<p>Of the 30 patients who presented with idiopathic LETM, 25 were females and five were males (female-to-male ratio of five), and anti-AQP4 antibodies were detected in 18 patients (<xref ref-type="table" rid="table1-1352458512451659">Table 1</xref>).</p>
<table-wrap id="table1-1352458512451659" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of the clinical features in anti-AQP4 (+) and anti-AQP4 (-) patients with longitudinally extensive transverse myelitis.</p>
</caption>
<graphic alternate-form-of="table1-1352458512451659" xlink:href="10.1177_1352458512451659-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">Anti-AQP4 (+)<hr/></th>
<th align="left">Anti-AQP4 (-)<hr/></th>
<th align="left">Total<hr/></th>
<th align="left"><italic>P</italic> value</th>
</tr>
<tr>
<th/>
<th align="left">(<italic>n</italic> = 18)</th>
<th align="left">(<italic>n</italic> = 12)</th>
<th align="left">(<italic>n</italic> = 30)</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>Female/male ratio</td>
<td>17/1</td>
<td>8/4</td>
<td>25/5</td>
<td>NS</td>
</tr>
<tr>
<td>Age of onset (± SD) (years)</td>
<td>40.56 ± 14.80</td>
<td>38.38 ± 14.02</td>
<td>39.69 ± 13.69</td>
<td>NS</td>
</tr>
<tr>
<td>NMO<xref ref-type="table-fn" rid="table-fn1-1352458512451659">*</xref></td>
<td>15/18 (83.33%)</td>
<td>3/12 (25.00%)</td>
<td>18/30 (60.00%)</td>
<td>0.002</td>
</tr>
<tr>
<td>MS</td>
<td>0/18 (0.00%)</td>
<td>1/12 (8.33%)</td>
<td>1/30 (3.33%)</td>
<td>NS</td>
</tr>
<tr>
<td>Monophasic<xref ref-type="table-fn" rid="table-fn1-1352458512451659">*</xref></td>
<td>3/18 (16.67%)</td>
<td>7/12 (58.33%)</td>
<td>10/30 (33.33%)</td>
<td>0.045</td>
</tr>
<tr>
<td colspan="5">Onset symptoms (%)</td>
</tr>
<tr>
<td> Weakness</td>
<td>13/18 (72.22%)</td>
<td>11/12 (93.67%)</td>
<td>24/30 (80.00%)</td>
<td>NS</td>
</tr>
<tr>
<td> Sensory loss</td>
<td>13/18 (72.22%)</td>
<td>10/12 (83.33%)</td>
<td>23/24 (76.66%)</td>
<td>NS</td>
</tr>
<tr>
<td> Sphincter dysfunction</td>
<td>2/18 (11.11%)</td>
<td>4/12 (33.33%)</td>
<td>6/30 (20.00%)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="5">Electrophysiologic examinations (number of abnormal tested/number tested)</td>
</tr>
<tr>
<td> Overall</td>
<td>14/18 (77.77%)</td>
<td>6/12 (50.00%)</td>
<td>20/30 (66.67%)</td>
<td>NS</td>
</tr>
<tr>
<td> VEP</td>
<td>14/18 (77.77%)</td>
<td>5/12 (41.67%)</td>
<td>19/30 (63.33%)</td>
<td>NS</td>
</tr>
<tr>
<td> MEP</td>
<td>10/18 (55.55%)</td>
<td>5/12 (41.67%)</td>
<td>15/30 (50.00%)</td>
<td>NS</td>
</tr>
<tr>
<td> SSEP</td>
<td>8/18 (44.44%)</td>
<td>5/12 (41.67%)</td>
<td>13/30 (43.33%)</td>
<td>NS</td>
</tr>
<tr>
<td> BAEP</td>
<td>1/18 (5.56%)</td>
<td>0/12 (0.00%)</td>
<td>1/30 (3.33%)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="5">CSF examinations#</td>
</tr>
<tr>
<td> Total protein (mg/dL, ± SD)</td>
<td>60.88 ± 31.24</td>
<td>42.57 ± 8.79</td>
<td>54.44 ± 27.14</td>
<td>NS</td>
</tr>
<tr>
<td> Cell counts (number/µL, ± SD)</td>
<td>17.42 ± 35.21</td>
<td>7.54 ± 11.82</td>
<td>13.95 ± 29.59</td>
<td>NS</td>
</tr>
<tr>
<td> Pleocytosis &gt; 50 WBC/μL (%)</td>
<td>3/25 (12.00%)</td>
<td>0/13 (0.00%)</td>
<td>3/38 (7.89%)</td>
<td>NS</td>
</tr>
<tr>
<td> IgG index<xref ref-type="table-fn" rid="table-fn1-1352458512451659">*</xref></td>
<td>0.68 ± 0.43</td>
<td>0.47 ± 0.19</td>
<td>0.60 ± 0.36</td>
<td>0.018</td>
</tr>
<tr>
<td> IgG index &gt; 0.7<xref ref-type="table-fn" rid="table-fn1-1352458512451659">*</xref></td>
<td>8/25 (32.00%)</td>
<td>0/13 (0.00%)</td>
<td>8/38 (21.05%)</td>
<td>0.034</td>
</tr>
<tr>
<td> Oligoclonal bands (number of positive tested/number tested)</td>
<td>0/18 (0.00%)</td>
<td>1/12 (8.33%)</td>
<td>1/30 (3.33%)</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1352458512451659">
<p>BAEP: brainstem auditory evoked potential; CSF: cerebrospinal fluid; MEP: motor evoked potential; MS: multiple sclerosis; NMO: neuromyelitis optica; SSEP: somatosensory evoked potential; VEP: visual evoked potential, WBC: white blood cell; IgG: immunogamma globulin; #25 CSF examinations in 18 anti-AQP4 (+) patients and 13 CSF examinations in 12 anti-AQP4 (-) patients; *statistically significant between anti-AQP4 (+) and anti-AQP4 (-) patients (<italic>p</italic> &lt; 0.05); NS: not statistically significant between anti-AQP4 (+) and anti-AQP4 (-) patients (<italic>p</italic> ≥ 0.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The mean age of onset for anti-AQP4 (+) patients (40.56 ± 14.80 years) was similar to that of anti-AQP4 (-) patients (38.38 ± 14.02 years). Fifteen (83.33%) anti-AQP4 (+) patients fulfilled the Wingerchuk diagnostic criteria for NMO,<sup><xref ref-type="bibr" rid="bibr3-1352458512451659">3</xref></sup> while only three (25%, <italic>p</italic> = 0.002) anti-AQP4 (-) patients were also diagnosed with NMO. Monophasic myelitis was presented by 16.67% of the anti-AQP4 (+) patients, which was significantly lower than the percentage of monophasic myelitis-presenting anti-AQP4 (-) patients (58.33%, <italic>p</italic> = 0.045). The cumulative NMO conversion probability was significantly higher in anti-AQP4 (+) than in anti-AQP4 (-) LETM patients (<xref ref-type="fig" rid="fig1-1352458512451659">Figure 1</xref>, <italic>p</italic> = 0.01).</p>
<fig id="fig1-1352458512451659" position="float">
<label>Figure 1.</label>
<caption>
<p>A survival analysis comparison of the risk of developing neuromyelitis optica between anti-AQP4 (+) (<italic>n</italic> = 18) and anti-AQP4 (-) (<italic>n</italic> = 12) longitudinally extensive transverse myelitis (<italic>p</italic> = 0.01).</p>
</caption>
<graphic xlink:href="10.1177_1352458512451659-fig1.tif"/>
</fig>
<p>Eleven (61.11%) of the anti-AQP4 (+) LETM patients converted to NMO in the first two years, while only two (16.67%) of the anti-AQP4 (-) LETM patients converted to NMO within the first two years after the LETM onset. These groups did not show any remarkable clinical differences at the onset of disease. Weakness (80%) and sensory loss (76.66%) were the two most common initial presentations. Abnormal EPs were found in more than 77.77% of anti-AQP4 (+) patients, and VEP (77.77%) was the most sensitive modality. In contrast, abnormal EPs were found in only half of the anti-AQP4 (-) patients. VEP, MEP and SSEP revealed similar sensitivities in this group (41.67%).</p>
<p>Thirty-eight CSF specimens were obtained from the patients with LETM (<xref ref-type="table" rid="table1-1352458512451659">Table 1</xref>). There was no seroconversion or seroreversion for anti-AQP4 antibody among seven anti-AQP4 (+) and one anti-AQP4 (-) patients receiving repeated CSF study. The protein concentration in the CSF of anti-AQP4 (+) patients (60.88 ± 31.24 mg/dL) was slightly higher than that of anti-AQP4 (-) patients (42.57 ± 8.79 mg/dL). Anti-AQP4 (+) patients had a slightly higher number of white blood cells (WBCs) in the CSF (17.42 ± 35.21) than anti-AQP4 (-) patients (7.54 ± 11.82). Interestingly, the value of the IgG index of anti-AQP4 (+) patients (0.68 ± 0.43) was significantly higher than that of anti-AQP4 (-) patients (0.47 ± 0.19, <italic>p</italic> = 0.018). The percentage of patients with IgG index &gt; 0.7 was significantly higher in the anti-AQP4 (+) group (32%) than in the anti-AQP4 (-) group (0%, <italic>p</italic> = 0.034). Three anti-AQP4 (+) patients had CSF pleocytosis, while none of the anti-AQP4 (-) patients presented pleocytosis in the CSF. Only one anti-AQP4 (-) LETM patient in the study population had OCBs in the CSF.</p>
<p>Common autoantibodies were detected in 40% and 30% of anti-AQP4 (+) and anti-AQP4 (-) patients with LETM, respectively (<xref ref-type="table" rid="table2-1352458512451659">Table 2</xref>).</p>
<table-wrap id="table2-1352458512451659" position="float">
<label>Table 2.</label>
<caption>
<p>Autoantibodies presented in anti-AQP4 (+) and anti-AQP4 (-) patients with longitudinally extensive transverse myelitis patients (LETM).</p>
</caption>
<graphic alternate-form-of="table2-1352458512451659" xlink:href="10.1177_1352458512451659-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Autoantibodies (number of positive tested/number tested)</th>
<th align="left">Anti-AQP4 (+) (<italic>n</italic>=18)</th>
<th align="left">Anti-AQP4 (-) (<italic>n</italic>=12)</th>
<th align="left">Total (<italic>n</italic>=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANA (%)</td>
<td>6/15 (40.00%)</td>
<td>2/8 (25.00%)</td>
<td>8/23 (34.78%)</td>
</tr>
<tr>
<td>Anti-dsDNA (%)</td>
<td>0/10 (0.00%)</td>
<td>1/3 (33.33%)</td>
<td>1/14 (7.14%)</td>
</tr>
<tr>
<td>RF (%)</td>
<td>0/8 (0.00%)</td>
<td>1/9 (11.11%)</td>
<td>1/17 (5.88%)</td>
</tr>
<tr>
<td>Anti-SSA (%)</td>
<td>0/12 (0.00%)</td>
<td>0/6 (0.00%)</td>
<td>0/18 (0.00%)</td>
</tr>
<tr>
<td>Anti-SSB (%)</td>
<td>0/12 (0.00%)</td>
<td>0/6 (0.00%)</td>
<td>0/18 (0.00%)</td>
</tr>
<tr>
<td>Overall, <italic>n</italic>/tested</td>
<td>6/15 (40.00%)</td>
<td>3/10 (30.00%)</td>
<td>9/25 (36.00%)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1352458512451659">
<p>ANA: anti-nuclear antibody; anti-dsDNA: anti-double-stranded DNA antibody; RF: rheumatoid factor; Anti-SSA: anti-SSA antibody; Anti-SSB: anti-SSB antibody.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Anti-nuclear antibodies, anti-double-stranded DNA antibodies and rheumatoid factor were detected in a significant portion of patients in both groups. However, none of the tested patients (<italic>n</italic> = 18) presented with anti-SSA or anti-SSB antibodies. Over the mean follow-up duration of 5.63 years, the mean annual relapse rate of anti-AQP4 (+) patients (0.72 ± 0.31, <xref ref-type="table" rid="table3-1352458512451659">Table 3</xref>) was significantly higher than that of anti-AQP4 (-) patients (0.42 ± 0.17, <italic>p</italic> = 0.01).</p>
<table-wrap id="table3-1352458512451659" position="float">
<label>Table 3.</label>
<caption>
<p>Annual relapse rate of anti-AQP4 (+) and anti-AQP4 (-) longitudinally extensive transverse myelitis.</p>
</caption>
<graphic alternate-form-of="table3-1352458512451659" xlink:href="10.1177_1352458512451659-table3.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">anti-AQP4 (+)<hr/></th>
<th align="left">anti-AQP4 (-)<hr/></th>
<th align="left">Total<hr/></th>
<th align="left"><italic>P</italic> value</th>
</tr>
<tr>
<th/>
<th align="left">(<italic>N</italic> = 18)</th>
<th align="left">(<italic>N</italic> = 12)</th>
<th align="left">(<italic>N</italic> = 30)</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of follow-up (years)</td>
<td>6.08 ± 3.96</td>
<td>4.92 ± 2.92</td>
<td>5.63 ± 4.14</td>
<td>NS</td>
</tr>
<tr>
<td>Number of episodes</td>
<td>78</td>
<td>28</td>
<td>106</td>
<td>NS</td>
</tr>
<tr>
<td>Annual relapse rate<xref ref-type="table-fn" rid="table-fn3-1352458512451659">*</xref></td>
<td>0.72 ± 0.31</td>
<td>0.42 ± 0.17</td>
<td>0.60 ± 0.30</td>
<td>0.01</td>
</tr>
<tr>
<td>EDSS<xref ref-type="table-fn" rid="table-fn3-1352458512451659">*</xref></td>
<td>4.28 ± 2.22</td>
<td>2.67 ± 2.26</td>
<td>3.63 ± 2.34</td>
<td>0.031</td>
</tr>
<tr>
<td colspan="5">Treatment (number of treated/total number)</td>
</tr>
<tr>
<td>Interferon-ß1a</td>
<td>7/18 (38.89%)</td>
<td>1/12 (8.33%)</td>
<td>8/30 (26.67%)</td>
<td>NS</td>
</tr>
<tr>
<td>Azathioprine</td>
<td>5/18 (27.78%)</td>
<td>1/12 (8.33%)</td>
<td>6/30 (20.00%)</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1352458512451659">
<p>EDSS: Kurtzke Expanded Disability Status Scale; *statistically significant between anti-AQP4 (+) and anti-AQP4 (-) patients (<italic>p</italic> &lt; 0.05); NS: not statistically significant between anti-AQP4 (+) and anti-AQP4 (-) patients (<italic>p</italic> ≥ 0.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The follow-up durations between the two groups were not significantly different. Anti-AQP4 (+) patients displayed a significantly higher EDSS (4.28 ± 2.22) than anti-AQP4 (-) patients (2.67 ± 2.26, <italic>p</italic> = 0.031). Interferon-β1a was prescribed for seven (38.89%) anti-AQP4 (+) LETM patients and one (8.33%) anti-AQP4 (-) LETM patient. Five (27.78%) anti-AQP4 (+) patients and one (8.33%) anti-AQP4 (-) LETM patient received azathioprine treatment.</p>
<p>Among 75 spinal MRI examinations conducted in 30 patients, the mean number of affected longitudinal segments was 5.36 ± 3.06 (<xref ref-type="table" rid="table4-1352458512451659">Table 4</xref>).</p>
<table-wrap id="table4-1352458512451659" position="float">
<label>Table 4.</label>
<caption>
<p>Distribution of spinal and brain lesions on anti-AQP4 (+) and anti-AQP4 (-) longitudinally extensive transverse myelitis (LETM) magnetic resonance images (MRI).</p>
</caption>
<graphic alternate-form-of="table4-1352458512451659" xlink:href="10.1177_1352458512451659-table4.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left">anti-AQP4 (+)</th>
<th align="left">anti-AQP4 (-)</th>
<th align="left">Total</th>
<th align="left"><italic>P</italic> value</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Spinal MRIs</bold></td>
<td>48</td>
<td>27</td>
<td>75</td>
<td/>
</tr>
<tr>
<td>Length of spinal cord lesions (VBs)</td>
<td>5.60 ± 3.02</td>
<td>4.93 ± 3.14</td>
<td>5.36 ± 3.06</td>
<td>NS</td>
</tr>
<tr>
<td colspan="5">Longitudinal distribution (number of positive tested/number tested)</td>
</tr>
<tr>
<td> Cervical (%)</td>
<td>44/48 (91.67%)</td>
<td>16/27 (59.26%)</td>
<td>60/75 (80.00%)</td>
<td>NS</td>
</tr>
<tr>
<td> Thoracic (%)</td>
<td>42/48 (87.50%)</td>
<td>15/27 (55.56%)</td>
<td>57/75 (76.00%)</td>
<td>NS</td>
</tr>
<tr>
<td colspan="5">Horizontal distribution (number of positive tested/number tested)</td>
</tr>
<tr>
<td> Holocord (%)</td>
<td>13/48 (27.08%)</td>
<td>7/27 (25.93%)</td>
<td>20/75 (26.67%)</td>
<td>NS</td>
</tr>
<tr>
<td> Central grey (%)<xref ref-type="table-fn" rid="table-fn4-1352458512451659">*</xref></td>
<td>28/48 (58.33%)</td>
<td>6/27 (22.22%)</td>
<td>34/75 (45.33%)</td>
<td>0.004</td>
</tr>
<tr>
<td> Peripheral white (%)</td>
<td>7/48 (14.58%)</td>
<td>14/27 (51.85%)</td>
<td>21/75 (28.00%)</td>
<td>NS</td>
</tr>
<tr>
<td>Brain MRIs (number of positive tested/number tested)</td>
<td>25</td>
<td>8</td>
<td>33</td>
<td/>
</tr>
<tr>
<td> Juxtacortical (%)</td>
<td>4/25 (16.00%)</td>
<td>0/8 (0.00%)</td>
<td>4/33 (12.12%)</td>
<td>NS</td>
</tr>
<tr>
<td> Subcortical (%)</td>
<td>4/25 (16.00%)</td>
<td>0/8 (0.00%)</td>
<td>4/33 (12.12%)</td>
<td>NS</td>
</tr>
<tr>
<td> Periventricular (%)</td>
<td>10/25 (40.00%)</td>
<td>1/8 (12.50%)</td>
<td>11/33 (33.33%)</td>
<td>NS</td>
</tr>
<tr>
<td> Infratentorial (%)</td>
<td>4/25 (16.00%)</td>
<td>0/8 (0.00%)</td>
<td>4/33 (12.12%)</td>
<td>NS</td>
</tr>
<tr>
<td> Met Barkhof criteria (%)</td>
<td>5/25 (20.00%)</td>
<td>1/8 (12.50%)</td>
<td>6/33 (18.18%)</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-1352458512451659">
<p>VB: vertebral body; *statistically significant in between anti-AQP4 (+) and anti-AQP4 (-) patients (<italic>p &lt;</italic> 0.05); NS: not statistically significant between anti-AQP4 (+) and anti-AQP4 (-) patients (<italic>p</italic> ≥ 0.05).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Both groups demonstrated similar lengths and longitudinal distributions of the involved vertebral segments, apart from the middle thoracic segment, which was more frequently involved in the anti-AQP4 (+) patients (<xref ref-type="fig" rid="fig2-1352458512451659">Figure 2</xref>).</p>
<fig id="fig2-1352458512451659" position="float">
<label>Figure 2.</label>
<caption>
<p>A comparison of the distributions of spinal cord lesions between anti-AQP4 (+) and anti-AQP4 (-) longitudinally extensive transverse myelitis.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451659-fig2.tif"/>
</fig>
<p>Central grey matter-predominant lesions were involved significantly more frequently in anti-AQP4 (+) patients (58.33%) than in the anti-AQP4 (-) patients (22.22%, <italic>p</italic> = 0.004). In contrast, anti-AQP4 (-) patients displayed a higher proportion of peripheral white matter-predominant lesions (51.85%) than the anti-AQP4 (+) patients (14.58%, <italic>p</italic> = 0.001).</p>
<p>Twenty of the 30 patients received brain MRIs (<xref ref-type="fig" rid="fig3-1352458512451659">Figure 3</xref>).</p>
<fig id="fig3-1352458512451659" position="float">
<label>Figure 3.</label>
<caption>
<p>Timeline and brain magnetic resonance imaging (MRI) classification of patients with longitudinally extensive transverse myelitis, as having Barkhof brain lesions, lesion not fulfilling Barkhof criteria, or being normal, according to the last follow-up visit. NMO: neuromyelitis optica.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451659-fig3.tif"/>
</fig>
<p>Three of the 13 (23.07%) anti-AQP4 (+) LETM patients had developed Barkhof brain lesions sometime in the follow-up period. Lesions not fulfilling Barkhof criteria and normal brain MRIs were found in one and nine anti-AQP4 (+) patients, respectively. Only one (14.29%) anti-AQP4 (-) patient developed Barkhof brain lesions. In all of the 33 brain MRI examinations (<xref ref-type="table" rid="table4-1352458512451659">Table 4</xref>), both groups displayed a similar frequency and distribution of lesions.</p>
<p>Five of the brain MRIs of three anti-AQP4 (+) patients and one brain MRI from an anti-AQP4 (-) patient showed lesions that fulfilled the Barkhof criteria after the first LETM. Representative MRI findings of anti-AQP4 (+) and anti-AQP4 (-) LETM are shown in <xref ref-type="fig" rid="fig4-1352458512451659">Figure 4</xref>.</p>
<fig id="fig4-1352458512451659" position="float">
<label>Figure 4.</label>
<caption>
<p>Representative magnetic resonance imaging (MRI) in patients with anti-AQP4 (+) <bold>(A-C)</bold> and anti-AQP4 (-) <bold>(D–E)</bold> longitudinally extensive transverse myelitis (LETM). A 48-year-old female patient with anti-AQP4 (+) LETM presented a longitudinal hyperintense lesion at C6-T4 on a T2-weighted MRI <bold>(A)</bold>, multiple periventricular hyperintense lesions on a fluid-attenuated inversion recovery MRI <bold>(B)</bold>, and a grey matter-predominant hyperintense lesion on the axial plane of a T2-weighted MRI <bold>(C)</bold>. A 39-year-old female patient with anti-AQP4 (-) LETM presented a longitudinal hyperintense lesion on a T2-weighted MRI <bold>(D)</bold>, a contrast-enhanced lesion on a T1-weighted MRI at the C1–C6 segments <bold>(E)</bold> and a white matter-predominant contrast-enhanced lesion on the axial plane of a T1-weighted MRI <bold>(F)</bold>.</p>
</caption>
<graphic xlink:href="10.1177_1352458512451659-fig4.tif"/>
</fig>
</sec>
<sec id="section12-1352458512451659" sec-type="discussion">
<title>Discussion</title>
<p>In the present study, more than half (60%) of the patients with LETM had anti-AQP4 antibodies. Compared to anti-AQP4 (-) LETM, anti-AQP4 (+) LETM displayed a higher IgG index, a higher relapse rate and a higher EDSS, suggesting that the anti-AQP4 antibody could categorise LETM into two distinct clinical entities.</p>
<p>More than 80% of the anti-AQP4 (+) LETM patients in this study experienced clinical relapses and were diagnosed with NMO. Although the anti-AQP4 antibody is thought to be sensitive in the diagnosis of NMO, an apparent discrepancy of sensitivity has been shown in a number of studies. It has been reported that 90% of NMO patients in Japan and 83.3% of NMO patients in Korea have anti-AQP4 antibodies.<sup><xref ref-type="bibr" rid="bibr17-1352458512451659">17</xref>,<xref ref-type="bibr" rid="bibr18-1352458512451659">18</xref></sup> In Italy, the sensitivity of anti-AQP4 antibodies in NMO patients is 47%.<sup><xref ref-type="bibr" rid="bibr19-1352458512451659">19</xref></sup> Only 33.3% of patients in the Caribbean are positive for anti-AQP4 antibodies.<sup><xref ref-type="bibr" rid="bibr20-1352458512451659">20</xref></sup> Although the utility of anti-AQP4 antibodies for the diagnosis of patients with monophasic NMO or recurrent NMO presented with newly developed optic neuritis is still unknown, our study indicated that anti-AQP4 is a sensitive tool for the diagnosis of NMO.</p>
<p>NMO frequently begins with an acute or subacute episode of optic neuritis or LETM, similar to the clinically isolated syndrome described in MS. Among patients with LETM, a proportion will never have a second episode, and therefore cannot be diagnosed as NMO.<sup><xref ref-type="bibr" rid="bibr5-1352458512451659">5</xref></sup> Currently, sensitive marker(s) to predict the conversion of NMO from LETM are still absent. Our study showed that nearly 60% of anti-AQP4 (+) LETM patients converted to NMO in the first two years, while only less than 20% of the anti-AQP4 (-) LETM patients converted to NMO within the first two years after the LETM onset and seemed to be stable after that. Therefore, the time to NMO conversion is maximal especially within the first two years. These results are similar to the study in patients with optic neuritis as the initial presentation, which demonstrated a rapid NMO conversion in the first five years after the initial episode.<sup><xref ref-type="bibr" rid="bibr20-1352458512451659">20</xref></sup></p>
<p>LESCLs are rarely seen in conventional MS patients in Western populations, but are reported in 30%–50% of optico-spinal MS patients in Asia.<sup><xref ref-type="bibr" rid="bibr15-1352458512451659">15</xref>,<xref ref-type="bibr" rid="bibr21-1352458512451659">21</xref></sup> However, only limited studies provide clues regarding the conversion of MS in LETM patients. Similar to the data presented by Kim’s group,<sup><xref ref-type="bibr" rid="bibr5-1352458512451659">5</xref></sup> a very low proportion (3.33%) of patients with LETM converted to MS in our study. None of the AQP4 (+) LETM patients converted to MS within the follow-up period. Similar to the observation in Pittock’s paper,<sup><xref ref-type="bibr" rid="bibr22-1352458512451659">22</xref></sup> we find follow-up brain MRIs which fulfill Barkhof criteria at some time in the clinical course of NMO patients. Although the predominant peripheral white matter involvement seen in the axial spinal MRI is similar to MS, only one anti-AQP4 (-) LETM patient was diagnosed as MS due to the presentation of Barkhof brain lesions. Only two of 12 anti-AQP4 (-) LETM patients converted to NMO during the follow-up period. These findings suggested that anti-AQP4 (-) LETM could be a form of inflammatory myelopathy that is distinct from MS.</p>
<p>Our study essentially confirmed the observation that higher relapse rate occurred in anti-AQP4 (+) LETM patients.<sup><xref ref-type="bibr" rid="bibr6-1352458512451659">6</xref></sup> However, the inconsistent treatment may lead to this difference. It has been suggested that interferon-β treatment could increase the titre of anti-AQP4 antibodies and the relapse rate in the anti-AQP4 (+) patients.<sup><xref ref-type="bibr" rid="bibr14-1352458512451659">14</xref>,<xref ref-type="bibr" rid="bibr23-1352458512451659">23</xref>,<xref ref-type="bibr" rid="bibr24-1352458512451659">24</xref></sup> This might be explained by the fact that a shift toward a type 2 T-helper cell-dominated immunological reaction by interferon-β may potentiate autoantibody production and enhance the relapse.<sup><xref ref-type="bibr" rid="bibr25-1352458512451659">25</xref></sup> In our study more anti-AQP4 (+) patients received interferon-β1a, which might have contributed to the higher relapse rate in this group.</p>
<p>In addition to the distinct clinical features, anti-AQP4 (+) LETM was quite different in the distribution of spinal cord lesions from anti-AQP4 (-) LETM. Although the upper cervical segments were frequently involved in both anti-AQP4 (+) and anti-AQP4 (-) LETM in the longitudinal planes, the middle thoracic segments were more frequently involved in anti-AQP4 (+) LETM. In the axial planes, anti-AQP4 (+) LETM displayed central grey matter-predominant involvement, which is similar to NMO.<sup><xref ref-type="bibr" rid="bibr26-1352458512451659">26</xref></sup> Considering the high NMO conversion rate in anti-AQP4 (+) LETM, the NMO-like radiological findings strongly suggest that anti-AQP4 (+) LETM should be regarded as an early, isolated syndrome of NMO spectrum disorder.</p>
<p>The higher IgG index in anti-AQP4 (+) LETM suggests that an increased intrathecal IgG synthesis, particularly due to heightened humoral autoimmunity, may be involved in the generation of myelitis. The positive correlation between anti-AQP4 antibody titres and the segmental lengths involved in NMO further supports the view that anti-AQP4 antibodies directly participate in the pathogenesis of NMO.<sup><xref ref-type="bibr" rid="bibr18-1352458512451659">18</xref></sup> Further pathological studies are needed to understand whether anti-AQP4 (+) monophasic or recurrent LETM are a part of the same disease entity as NMO. In anti-AQP4 (-) LETM, investigations focusing on the potentially involved CNS-specific epitope are required.</p>
<p>Immunosuppressants, such as azathioprine and myco-phenolate mofetil, are reasonably effective in reducing the frequency of attacks in NMO patients.<sup><xref ref-type="bibr" rid="bibr27-1352458512451659">27</xref>,<xref ref-type="bibr" rid="bibr28-1352458512451659">28</xref></sup> Rituximab, a chimeric monoclonal antibody that targets CD20-positive cells, was shown to be effective in decreasing the annual relapse rate and the disability progression of NMO in a small study.<sup><xref ref-type="bibr" rid="bibr29-1352458512451659">29</xref>,<xref ref-type="bibr" rid="bibr30-1352458512451659">30</xref></sup> In the current study, the high NMO conversion rate in anti-AQP4 (+) LETM indicates that the presence of anti-AQP4 antibodies could be a critical factor in determining the treatment strategy. Early intervention with immunosuppressants or Rituximab in anti-AQP4 (+) LETM could be helpful in improving the outcome of patients. In anti-AQP4 (-) LETM, the effects of immunomodulatory or immunosuppressant therapy require further investigation.</p>
<p>The number of required findings to meet the NMO criteria is different in LETM patients with anti-AQP4 antibodies and those without anti-AQP4 antibodies. In anti-AQP4 (+) LETM patients, a normal brain MRI is not essential to fulfil the diagnosis of NMO. On the other hand, the abnormal MRI will exclude anti-AQP4 (-) LETM patients from the diagnosis of NMO despite their development of both LETM and optic neuritis. In this study, the percentages of the patients whose brain MRIs were available were not significantly different in these two groups. The exclusion of NMO diagnosis in the only anti-AQP4 (-) patient with Barkhof brain lesions was based on the absence of optic neuritis. Thus the difference in NMO conversion rate between patients with and without anti-AQP4 antibodies in this study is not likely due to the distinct contributions of the brain MRI information in both groups.</p>
<p>This retrospective study may have potential recruitment bias due to the small study population. The treatment and follow-up duration were inconsistent in both groups. Future prospective studies involving larger patient populations are needed to confirm the prognosis of both groups. In conclusion, this study demonstrated that anti-AQP4 (+) LETM has clinical features that are similar to NMO, whereas anti-AQP4 (-) LETM displayed a low conversion to NMO. These results suggest that detection of anti-AQP4 antibodies may result in earlier diagnosis of NMO in patients with LETM. Further investigation of the application of immunomodulators or immunosuppressants in anti-AQP4 (+) LETM is needed to clarify whether early medical intervention can prevent the conversion of NMO and to improve the prognosis of affected patients.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding statement</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<notes>
<fn-group>
<fn fn-type="other">
<p>Author contributions include: Conception and design: Chang KH and Ro LS. Analysis and interpretation of data: Chang KH and Ro LS. Acquisition of data: Chang KH, Lyu RK, Chen CM, Wu YR, Chang HS, Huang CC, Kuo HC, Chu CC, Hsu WC and Ro LS. Drafting the article or revising it critically for important intellectual content: Chang KH and Ro LS. Final approval of the version to be published: Chang KH and Ro LS.</p>
</fn>
</fn-group>
</notes>
<ref-list>
<title>References</title>
<ref id="bibr1-1352458512451659">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Hogancamp</surname><given-names>WF</given-names></name>
<name><surname>O’Brien</surname><given-names>PC</given-names></name>
<etal/>
</person-group>. <article-title>The clinical course of neuromyelitis optica (Devic’s syndrome)</article-title>. <source>Neurology</source> <year>1999</year>; <volume>53</volume>: <fpage>1107</fpage>–<lpage>1114</lpage>.</citation>
</ref>
<ref id="bibr2-1352458512451659">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Lucchinetti</surname><given-names>CF</given-names></name>
<etal/>
</person-group>. <article-title>The spectrum of neuromyelitis optica</article-title>. <source>Lancet Neurol</source> <year>2007</year>; <volume>6</volume>: <fpage>805</fpage>–<lpage>815</lpage>.</citation>
</ref>
<ref id="bibr3-1352458512451659">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<etal/>
</person-group>. <article-title>Revised diagnostic criteria for neuromyelitis optica</article-title>. <source>Neurology</source> <year>2006</year>; <volume>66</volume>: <fpage>1485</fpage>–<lpage>1489</lpage>.</citation>
</ref>
<ref id="bibr4-1352458512451659">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Kryzer</surname><given-names>TJ</given-names></name>
<etal/>
</person-group>. <article-title>A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>2106</fpage>–<lpage>2112</lpage>.</citation>
</ref>
<ref id="bibr5-1352458512451659">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Kim</surname><given-names>S</given-names></name>
<name><surname>Vincent</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis</article-title>. <source>J Neurol</source> <year>2010</year>; <volume>257</volume>: <fpage>920</fpage>–<lpage>925</lpage>.</citation>
</ref>
<ref id="bibr6-1352458512451659">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
<name><surname>Wingerchuk</surname><given-names>DM</given-names></name>
<name><surname>Vukusic</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis</article-title>. <source>Ann Neurol</source> <year>2006</year>; <volume>59</volume>: <fpage>566</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr7-1352458512451659">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Polman</surname><given-names>CH</given-names></name>
<name><surname>Reingold</surname><given-names>SC</given-names></name>
<name><surname>Banwell</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria</article-title>. <source>Ann Neurol</source> <year>2011</year>; <volume>69</volume>: <fpage>292</fpage>–<lpage>302</lpage>.</citation>
</ref>
<ref id="bibr8-1352458512451659">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Confavreux</surname><given-names>C</given-names></name>
<name><surname>Vukusic</surname><given-names>S</given-names></name>
<name><surname>Moreau</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Relapses and progression of disability in multiple sclerosis</article-title>. <source>N Engl J Med</source> <year>2000</year>; <volume>343</volume>: <fpage>1430</fpage>–<lpage>1438</lpage>.</citation>
</ref>
<ref id="bibr9-1352458512451659">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurtzke</surname><given-names>JF</given-names></name>
</person-group>. <article-title>Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)</article-title>. <source>Neurology</source> <year>1983</year>; <volume>33</volume>: <fpage>1444</fpage>–<lpage>1452</lpage>.</citation>
</ref>
<ref id="bibr10-1352458512451659">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lyu</surname><given-names>RK</given-names></name>
<name><surname>Tang</surname><given-names>LM</given-names></name>
<name><surname>Chen</surname><given-names>CJ</given-names></name>
<etal/>
</person-group>. <article-title>The use of evoked potentials for clinical correlation and surgical outcome in cervical spondylotic myelopathy with intramedullary high signal intensity on MRI</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>2004</year>; <volume>75</volume>: <fpage>256</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr11-1352458512451659">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Huang</surname><given-names>M</given-names></name>
<name><surname>Huang</surname><given-names>C</given-names></name>
<name><surname>Ryu</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Sudden bilateral hearing impairment in vertebrobasilar occlusive disease</article-title>. <source>Stroke</source> <year>1993</year>; <volume>24</volume>: <fpage>132</fpage>–<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr12-1352458512451659">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chu</surname><given-names>NS</given-names></name>
</person-group>. <article-title>Pattern-reversal visual evoked potentials: latency changes with gender and age</article-title>. <source>Clin Electroencephalogr</source> <year>1987</year>; <volume>18</volume>: <fpage>159</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr13-1352458512451659">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersson</surname><given-names>M</given-names></name>
<name><surname>Alvarez-Cermeno</surname><given-names>J</given-names></name>
<name><surname>Bernardi</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report</article-title>. <source>J Neurol Neurosurg Psychiatry</source> <year>1994</year>; <volume>57</volume>: <fpage>897</fpage>–<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr14-1352458512451659">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuoka</surname><given-names>T</given-names></name>
<name><surname>Matsushita</surname><given-names>T</given-names></name>
<name><surname>Kawano</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese</article-title>. <source>Brain</source> <year>2007</year>; <volume>130</volume>: <fpage>1206</fpage>–<lpage>1223</lpage>.</citation>
</ref>
<ref id="bibr15-1352458512451659">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tartaglino</surname><given-names>LM</given-names></name>
<name><surname>Friedman</surname><given-names>DP</given-names></name>
<name><surname>Flanders</surname><given-names>AE</given-names></name>
<etal/>
</person-group>. <article-title>Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters</article-title>. <source>Radiology</source> <year>1995</year>; <volume>195</volume>: <fpage>725</fpage>–<lpage>732</lpage>.</citation>
</ref>
<ref id="bibr16-1352458512451659">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barkhof</surname><given-names>F</given-names></name>
<name><surname>Filippi</surname><given-names>M</given-names></name>
<name><surname>Miller</surname><given-names>DH</given-names></name>
<etal/>
</person-group>. <article-title>Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis</article-title>. <source>Brain</source> <year>1997</year>; <volume>120</volume> (<issue>Pt 11</issue>): <fpage>2059</fpage>–<lpage>2069</lpage>.</citation>
</ref>
<ref id="bibr17-1352458512451659">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lim</surname><given-names>BC</given-names></name>
<name><surname>Hwang</surname><given-names>H</given-names></name>
<name><surname>Kim</surname><given-names>KJ</given-names></name>
<etal/>
</person-group>. <article-title>Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica</article-title>. <source>Mult Scler</source> <year>2011</year>; <volume>17</volume>: <fpage>67</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr18-1352458512451659">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takahashi</surname><given-names>T</given-names></name>
<name><surname>Fujihara</surname><given-names>K</given-names></name>
<name><surname>Nakashima</surname><given-names>I</given-names></name>
<etal/>
</person-group>. <article-title>Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre</article-title>. <source>Brain</source> <year>2007</year>; <volume>130</volume>: <fpage>1235</fpage>–<lpage>1243</lpage>.</citation>
</ref>
<ref id="bibr19-1352458512451659">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fazio</surname><given-names>R</given-names></name>
<name><surname>Malosio</surname><given-names>ML</given-names></name>
<name><surname>Lampasona</surname><given-names>V</given-names></name>
<etal/>
</person-group>. <article-title>Antiacquaporin 4 antibodies detection by different techniques in neuromyelitis optica patients</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>1153</fpage>–<lpage>1163</lpage>.</citation>
</ref>
<ref id="bibr20-1352458512451659">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cabrera-Gomez</surname><given-names>JA</given-names></name>
<name><surname>Bonnan</surname><given-names>M</given-names></name>
<name><surname>Gonzalez-Quevedo</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica positive antibodies confer a worse course in relapsing-neuromyelitis optica in Cuba and French West Indies</article-title>. <source>Mult Scler</source> <year>2009</year>; <volume>15</volume>: <fpage>828</fpage>–<lpage>833</lpage>.</citation>
</ref>
<ref id="bibr21-1352458512451659">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Matsuoka</surname><given-names>T</given-names></name>
<name><surname>Matsushita</surname><given-names>T</given-names></name>
<name><surname>Osoegawa</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Heterogeneity and continuum of multiple sclerosis in Japanese according to magnetic resonance imaging findings</article-title>. <source>J Neurol Sci</source> <year>2008</year>; <volume>266</volume>: <fpage>115</fpage>–<lpage>125</lpage>.</citation>
</ref>
<ref id="bibr22-1352458512451659">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pittock</surname><given-names>SJ</given-names></name>
<name><surname>Lennon</surname><given-names>VA</given-names></name>
<name><surname>Krecke</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Brain abnormalities in neuromyelitis optica</article-title>. <source>Arch Neurol</source> <year>2006</year>; <volume>63</volume>: <fpage>390</fpage>–<lpage>396</lpage>.</citation>
</ref>
<ref id="bibr23-1352458512451659">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Palace</surname><given-names>J</given-names></name>
<name><surname>Leite</surname><given-names>MI</given-names></name>
<name><surname>Nairne</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers</article-title>. <source>Arch Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>1016</fpage>–<lpage>1017</lpage>.</citation>
</ref>
<ref id="bibr24-1352458512451659">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Warabi</surname><given-names>Y</given-names></name>
<name><surname>Matsumoto</surname><given-names>Y</given-names></name>
<name><surname>Hayashi</surname><given-names>H</given-names></name>
</person-group>. <article-title>Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination</article-title>. <source>J Neurol Sci</source> <year>2007</year>; <volume>252</volume>: <fpage>57</fpage>–<lpage>61</lpage>.</citation>
</ref>
<ref id="bibr25-1352458512451659">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shimizu</surname><given-names>Y</given-names></name>
<name><surname>Ota</surname><given-names>K</given-names></name>
<name><surname>Kubo</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>Association of Th1/Th2-related chemokine receptors in peripheral T cells with disease activity in patients with multiple sclerosis and neuromyelitis optica</article-title>. <source>Eur Neurol</source> <year>2011</year>; <volume>66</volume>: <fpage>91</fpage>–<lpage>97</lpage>.</citation>
</ref>
<ref id="bibr26-1352458512451659">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>M</given-names></name>
<name><surname>Miyazawa</surname><given-names>I</given-names></name>
<name><surname>Fujihara</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study</article-title>. <source>J Neurol</source> <year>2008</year>; <volume>255</volume>: <fpage>163</fpage>–<lpage>170</lpage>.</citation>
</ref>
<ref id="bibr27-1352458512451659">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacob</surname><given-names>A</given-names></name>
<name><surname>Matiello</surname><given-names>M</given-names></name>
<name><surname>Weinshenker</surname><given-names>BG</given-names></name>
<etal/>
</person-group>. <article-title>Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients</article-title>. <source>Arch Neurol</source> <year>2009</year>; <volume>66</volume>: <fpage>1128</fpage>–<lpage>1133</lpage>.</citation>
</ref>
<ref id="bibr28-1352458512451659">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bichuetti</surname><given-names>DB</given-names></name>
<name><surname>Lobato de Oliveira</surname><given-names>EM</given-names></name>
<name><surname>Oliveira</surname><given-names>DM</given-names></name>
<etal/>
</person-group>. <article-title>Neuromyelitis optica treatment: analysis of 36 patients</article-title>. <source>Arch Neurol</source> <year>2010</year>; <volume>67</volume>: <fpage>1131</fpage>–<lpage>1136</lpage>.</citation>
</ref>
<ref id="bibr29-1352458512451659">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cree</surname><given-names>BA</given-names></name>
<name><surname>Lamb</surname><given-names>S</given-names></name>
<name><surname>Morgan</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>An open label study of the effects of rituximab in neuromyelitis optica</article-title>. <source>Neurology</source> <year>2005</year>; <volume>64</volume>: <fpage>1270</fpage>–<lpage>1272</lpage>.</citation>
</ref>
<ref id="bibr30-1352458512451659">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pellkofer</surname><given-names>HL</given-names></name>
<name><surname>Krumbholz</surname><given-names>M</given-names></name>
<name><surname>Berthele</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab</article-title>. <source>Neurology</source> <year>2011</year>; <volume>76</volume>: <fpage>1310</fpage>–<lpage>1315</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>